Our study suggests the development of a broadly applied approach targeting a specific subset of TAMs in lung cancer may yield similar benefits given the engagement of a shared pro-tumorigenic transcriptional program across APOE-high myeloid cells in metastatic LNs. This evidence concerns the gene APOE and lung carcinoma.